Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring
technologies and audio products, is thrilled to announce its
recognition as one of Fast Company’s Most Innovative Companies in
North America for 2024. This prestigious accolade is especially
meaningful given Masimo’s notable breakthroughs and the company’s
commitment to improve people’s lives through innovation.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240319317729/en/
Masimo is one of Fast Company's Most
Innovative Companies in North America for 2024. (Graphic: Business
Wire)
“We are honored to be recognized by Fast Company as one of the
top 10 Most Innovative Companies in North America for 2024,” said
Joe Kiani, Founder and CEO of Masimo. “This recognizes our ongoing
commitment to driving innovation to improve lives. Since our
founding 35 years ago, we have made solving what others thought
unsolvable our task, and fortunately, thanks to our incredible
team, we have solved many ‘unsolvable problems.’ Our solutions have
helped improve patient care and reduce the cost of care. We intend
to continue to innovate to usher in 22nd century healthcare in this
decade.”
Masimo’s inclusion in this respected list highlights its
unwavering dedication to innovation and the transformative impact
of its technologies in the healthcare sector. Masimo has been
recognized as one of the 10 most innovative organizations in the
North America sector, a testament to its leadership in advancing
patient care through cutting-edge and innovative solutions. In
their announcement, Fast Company highlighted several Masimo
breakthrough technologies that received FDA clearance in 2023,
including Opioid Halo™, an opioid overdose and prevention solution
that is the first and only FDA-authorized device to alert you in
the event of an opioid overdose; Stork™, a revolutionary baby
monitor that provides continuous, accurate monitoring, with alarms,
based on Masimo’s foundational pulse oximetry technology; and
Masimo W1™, a first-of-its-kind wearable offering accurate,
continuous health data and now available both in a consumer
sport-oriented version and as a medical watch – the first
FDA-cleared watch to provide continuous real-time oxygen saturation
and pulse rate for over-the-counter and prescription use.
From its inception, Masimo has been at the forefront of
developing innovative monitoring technologies and hospital
automation solutions that empower healthcare professionals to make
informed decisions and improve patient outcomes. This is why over
200 million people are monitored with Masimo pulse oximeters
annually and 9 out of the top 10 hospitals in the United States
rely on Masimo SET® pulse oximeters.1-2 Today, Masimo’s portfolio
encompasses a wide range of cutting-edge healthcare solutions,
including its flagship Signal Extraction Technology® (SET®) pulse
oximeter, Bridge™ for opioid withdrawal symptom relief, PerL with
Masimo AAT™ for personalized listening, and MightySat® Medical, the
first and only FDA-cleared medical fingertip pulse oximeter
available over the counter. In addition, Masimo’s most recent
consumer products, such as Masimo W1, Stork, and Opioid Halo,
provide solutions for continuous and accurate data tracking so
individuals can take better control of their health.
Masimo’s innovative solutions have revolutionized patient
monitoring and have been instrumental in enhancing clinical
decision-making, reducing medical errors, and optimizing healthcare
delivery. By continually pushing the boundaries of innovation,
Masimo remains at the forefront of transforming healthcare and
improving the lives of patients worldwide.
For more information about Masimo and its innovative solutions,
please visit www.masimo.com.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.3
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,4 improve CCHD screening in
newborns5 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.6-9 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,1 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.2 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® medical watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional
information about Masimo and its products may be found at
www.masimo.com. Published clinical studies on Masimo products can
be found at www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
Forward-Looking Statements - Masimo
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to COVID-19; as well as other factors
discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
About FAST COMPANY
Fast Company is the only media brand fully dedicated to the
vital intersection of business, innovation, and design, engaging
the most influential leaders, companies, and thinkers on the future
of business. Headquartered in New York City, Fast Company is
published by Mansueto Ventures LLC, along with our sister
publication Inc., and can be found online at
www.fastcompany.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240319317729/en/
Masimo Matt Whewell 720-838-0691 Matt.whewell@masimo.com
Masimo (NASDAQ:MASI)
過去 株価チャート
から 4 2024 まで 5 2024
Masimo (NASDAQ:MASI)
過去 株価チャート
から 5 2023 まで 5 2024